| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Executive VP and CLO | Executive VP and CLO
1 company
Boulding Mark Elliott serves as an Executive VP and CLO at PTCT. Across recent SEC filings that breaks down to 0 buys and 166 sells. Those positions are worth an estimated $6.8M at current prices.
Historically, Boulding Mark Elliott's trades have earned a middling insider score of 56/100 across 50 rated trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of -12.1%.
The biggest single holding is PTCT (~$6.8M) as Executive VP and CLO. The recent filings there lean toward selling, a net 671,251 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 5, 2021 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sell | 772 | $62.37 | $48,149.64 | -1.9% | |
| Jul 7, 2020 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE | 30,625 | $55.12 | $1,688,036.59 | -43.5% | |
| Jul 5, 2019 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE | 15,312 | $44.74 | $685,097.12 | -34.2% | |
| Jul 1, 2019 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE | 181,667 | $45.00 | $8,175,015.00 | -86.0% |